April 2014—Qiagen announced the launch plans of products designed to reduce the challenges of bottlenecks in next-generation sequencing: sample preparation and bioinformatics. The products add to Qiagen’s portfolio of solutions designed to run with any NGS platform.
GeneRead DNA FFPE Kit, available now, is for the purification of DNA from formalin-fixed, paraffin-embedded tissue sections. REPLI-g WTA Single Cell Kit and REPLI-g Cell WGA & WTA Kit, also available now, enable transcriptomic NGS analysis from single cells and comparative genomic and transcriptomic analysis from the same small sample. Both kits expand the REPLI-g single cell kit portfolio, which can make single cells accessible to NGS analysis.
Exosome sample-preparation kits enable processing of nucleic acids from exosomes. The kits will combine Qiagen’s sample technologies with technology developed by Exosome Diagnostics that detects key gene mutations and gene expressions in blood, urine, and cerebrospinal fluid without the need for a tissue biopsy. The first kits will be launched in the second quarter of this year.
Qiagen will also launch in the second quarter of this year a line of GeneRead DNAseq panels V2.0. The panels use as little as 10 ng of starting DNA material, generate small amplicons, and enable preparation of NGS libraries ready for sequencing within one day.
The CLC Cancer Research Workbench is a customizable cancer-focused bioinformatics solution that offers ready-to-use analysis workflows, which the user can modify. It provides the tools to identify prognostic markers and subclonal somatic mutations, detect inherited traits, find biomarkers for drug response, and determine new oncogenes.
Ingenuity Clinical is a Web-based solution for the clinical interpretation and reporting of insights from NGS-based tests. Qiagen began collaborating with molecular diagnostics laboratories in its development in November 2013, and announced plans for a 2014 launch of a larger beta program. Ingenuity Clinical will address challenges of scale, speed, and decision support that labs face in adopting NGS.
Qiagen also is developing the benchtop GeneReader NGS platform for clinical research applications. Commercialization is planned for this year.
Qiagen, 240-686-7425